Merck's Januvia Approved In China
This article was originally published in PharmAsia News
Executive SummaryMerck recently announced China State FDA approval of Januvia (sitagliptin), which is China's first DPP-4 inhibitor approved for the treatment of type 2 diabetes. At present, China has the world's second-largest diabetic population, trailing India. The International Diabetes Federation estimates that by 2030, the total number of people worldwide with diabetes will be more than 435 million. Currently the fourth largest cause of death worldwide, more than 3.8 million people die annually from diabetes and its complications. With both foreign and domestic companies entering the market, competition in the Chinese diabetes market will continue to heat up. (Click Here For More - Chinese Language
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.